

Pfizer R&D Overview

Mikael Dolsten, M.D., Ph.D.
President, Worldwide R&D

May 10, 2013



Forward-Looking Statements and Non-GAAP Financial Information

- Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer's 2012 Annual Report on Form 10-K/A and in our reports on Form 10-Q and Form 8-K.
- Also, the discussions during this meeting will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles. Reconciliations of those non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures can be found in Pfizer's Current Report on Form 8-K dated April 30, 2013.
- These reports are available on our website at www.pfizer.com in the "Investors - SEC Filings" section.


Continue to Execute on a Multi-year R&D Turnaround



2010

- Increased focus and rigor in the portfolio
- Integrated science & business
- Moved Research to bioinnovation hubs
- Advanced next-generation drug design
- Launched CTI
- Reduced R&D costs
- Execute on recent product launches
- Embed Precision Medicine
- Continue to lead in novel collaborations
- Increase portfolio quality, value, IRR
- Improve clinical trial quality & consistency
- Focus on culture & talent
- Important new product launches every year
- Strong productivity and return for patients and shareholders
- Emerge as nodal player in the health ecosystem

Strong Pipeline Momentum



Recent Approvals

 **Bosulif**[™]
bosutinib 500mg tablets

 **XALKORI**[®]
CAPSULES
CRIZOTINIB

 **Inlyta**[™]
axitinib tablets

 **ELIQUIS**[®]
apixaban

elelyso[™]
(taliglucerase alfa) for injection

Prevenar **13**^{*}
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

XELJANZ[®] 
[tofacitinib citrate]
5mg tablets

Highlights from the Mid-to-Late Stage Portfolio

Key Next Wave Programs

Xeljanz

Crohn's, Ankylosing Spondylitis

IL6, Anti-MAdCAM, Oral P38

Chronic Inflammatory Diseases

SMO, PI3K mTOR

Solid Tumor and Blood Cancers (SMO)

***S. aureus* and *C. difficile* Vaccines**

Prophylaxis of key Hospital-acquired Infections

Anti-PCSK9, SGLT-2

Cardiovascular and Type 2 Diabetes

PDE5 Inhibitor and CCR 2/5 Inhibitor

Chronic Kidney Disease

GMI-1070*

Vaso-occlusive Crisis, Sickle Cell Disease

Biosimilar trastuzumab & rituximab

Key Late Stage Programs

Xeljanz

Phase 3 studies in Ulcerative Colitis & Psoriasis

Eliquis

VTE Treatment & Prevention

Palbociclib

Advanced ER+HER2- Breast Cancer

Inotuzumab Ozogamicin

Aggressive Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia

Dacomitinib

Non-Small Cell Lung Cancer

Meningococcal B Adolescent Vaccine

Prevention of Meningococcal Infection

*Pfizer has exclusive license from GlycoMimetics

Q&A

